Abstract
Dengue is a globally emerging health concern, still in preliminary stage of drug development. Many research scientists explored the dengue virus and identified its several targets that are categorized as structural and non-structural proteins, irrespective of its serotypic classification. A number of natural, synthetic and patented analogs are screened and studied against different serotypes and targets of dengue. Our review compiles the recent developments based on the huge number of such molecular space created by diverse scaffolds, specifically targeting NS2B-NS3 protease and methyltransferase (NS5) of dengue virus (DENV) infection. The emphasis of our article is to confer the leads towards the DENV drug discovery.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.